Sector News

Pfizer makes moves to offload Hospira's pumps and devices business

May 3, 2016
Life sciences

Pfizer has begun taking offers on Hospira’s pumps and devices business, after considering offloading it for some time. A sale would free Pfizer of an acquisition that falls outside the scope of its traditional drug business.

Med tech companies Smiths Group and Fresenius put in bids for the unit, which Pfizer picked up last year through its $15 billion deal for Hospira. Private equity firm Pamplona Capital made a second-round bid for the business, Bloomberg reports, although final bids for the unit aren’t due until the end of May.

Pfizer has said that it could reap about $2 billion from a sale of Hospira’s devices business. Representatives from Pfizer, Germany’s Fresenius and London-based Smiths Group declined to comment to the news outlet.

Pfizer snatched up Hospira in order to get its hands on the company’s biosimilars and generic injectables. Hospira’s pumps and devices unit doesn’t fit in with the rest of Pfizer’s established products business, and selling the business would create a more pure-play drugs unit that’s ripe for a sale, IPO or spinoff.

More changes could also be on the horizon for Pfizer after its $160 billion deal with Allergan ($AGN) fell through last month. The company is going to decide by the end of this year whether it should break into two separate businesses, its original timeline for the breakup, Pfizer CEO Ian Read said at the time.

And meanwhile, the drug giant will continue to scout out deals and explore “other shareholder friendly capital allocation opportunities,” he said in a statement.

By Emily Wasserman

Source: Fierce Pharma

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach